Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Pseudo Biologist who wrote (968)	4/17/2000 10:39:00 PM
From: Mark Adams	Respond to of 52153

Thanks for the insight. I held off an initial position after thinking that they managed to go public during such a positive phase for biotech stocks that they probably got a better share price than deserved. At half the $15 IPO- it's probably closer to fair value, without looking under the covers- but then I know other stocks better, understand their trading patterns, so why take a chance on an unknown? With drugs near phase III, they probably deserve a closer look. Are they partnering with major pharma's to help with the costs? I'd know this if I took the time to read the 10k, or even cruise their website. So I better be off to do that now.